Perrigo Company plc
21.28-0.32 (-1.48%)
Oct 29, 4:00:02 PM EDT · NYSE · PRGO · USD
Key Stats
Market Cap
2.93BP/E (TTM)
-Basic EPS (TTM)
-0.43Dividend Yield
0.05%Recent Filings
8-K
Perrigo Q2 sales dip, EPS up
Perrigo reported Q2 2025 net sales of $1.06 billion, down 0.9% year-over-year, with organic sales flat amid infant formula scrap and soft consumption in digestive health and oral care, yet gains in pain aids and upper respiratory cushioned the blow. Adjusted EPS rose 7.5% to $0.57, fueled by lower interest and Project Energize efficiencies, while the Dermacosmetics sale sharpens focus. Sales growth lags, but earnings hold firm.
10-Q
Q2 FY2025 results
Perrigo's Q2 sales dipped 0.9% y/y to $1.056B, yet operating income swung to $45.4M from a $26.5M loss, thanks to slashed restructuring costs and no repeat of last year's $34.1M impairments. Gross margin slipped to 34.4% amid infant formula scrap and U.S. OTC volume dips, but CSCA nutrition rebounded 11% on store-brand recovery while CSCI's Solpadeine supply fix boosted pain aids 26%. Cash fell to $454M with $11M operating flow; debt holds at $3.65B under compliant covenants. Free cash flow not disclosed in the 10-Q. Ongoing price-fixing suits from the old Rx unit linger as a litigation drag.
8-K
Perrigo sells Dermacosmetics for €327M
Perrigo signed a deal on July 13, 2025, to sell its Dermacosmetics business in Northern Europe, the Netherlands, and Poland to Kairos Bidco AB, a KKR affiliate, for €300 million upfront cash plus up to €27 million in contingent payments over three years. The divestiture, expected to close in Q1 2026 pending regulatory approvals and KKR's Karo Healthcare acquisition, advances Perrigo's Three-S plan to streamline its portfolio toward high-growth self-care brands. This business generated €125 million in 2024 net sales, about 5% of adjusted operating income. Yet regulatory hurdles could delay completion.
8-K
Perrigo leadership shakeup announced
Perrigo Company plc restructured its leadership to scale its category-led, market activation growth model, eliminating the EVP & President Consumer Self-Care Americas role held by Triona Schmelter, effective June 30, 2025, while appointing Roberto Khoury as EVP & Chief Commercial Officer on July 1, 2025, to oversee global commercial functions. This alignment boosts agility and innovation without altering 2025 adjusted EPS guidance. Schmelter transitions to advisory until October 31. Yet, implementation unfolds over months amid legal consultations.
8-K
Perrigo supply chain leadership shifts
Perrigo's EVP of Global Operations and Supply Chain, Ron Janish, retires after over two decades, stepping down June 23, 2025, and advising until September 30. Matt Winterman, with 20+ years leading massive supply chains at AstraZeneca, Roche, and GSK, steps in to drive transformation. This handover bolsters operational resilience for Perrigo's self-care strategy. Smooth transition ahead.
IPO
Website
Employees
Sector
Industry
HLN
Haleon plc
9.05-0.07
HYPMY
Hypera SA
4.42-0.03
KVUE
Kenvue Inc.
14.31-0.20
OGN
Organon & Co.
6.34-0.32
ORGO
Organogenesis Holdings Inc.
4.17-0.02
PBH
Prestige Consumer Healthcare In
60.71-1.32
PG
Procter & Gamble Company (The)
148.77-2.60
RDY
Dr. Reddy's Laboratories Ltd
13.41-1.19
TEVA
Teva Pharmaceutical Industries
20.23+0.45
VTRS
Viatris Inc.
10.27-0.02